

High-Level Quinolone-Resistant *Haemophilus haemolyticus* in Pediatric Patient with No History of Quinolone Exposure

Emi Tanaka,¹ Yuji Hirai,¹ Takeaki Wajima, Yu Ishida, Yoshiaki Kawamura, Hidemasa Nakaminami

The prevalence of antimicrobial resistance among *Haemophilus* spp. is a critical concern, but high-level quinolone-resistant strains had not been isolated from children. We isolated high-level quinolone-resistant *H. haemolyticus* from the suction sputum of a 9-year-old patient. The patient had received home medical care with mechanical ventilation for 2 years and had not been exposed to any quinolones for ≥ 3 years. The *H. haemolyticus* strain we isolated, 2019-19, shared biochemical features with *H. influenzae*. However, whole-genome analysis found this strain was closer to *H. haemolyticus*. Phylogenetic and mass spectrometry analyses indicated that strain 2019-19 was in the same cluster as *H. haemolyticus*. Comparison of quinolone resistance-determining regions showed strain 2019-19 possessed various amino acid substitutions, including those associated with quinolone resistance. This report highlights the existence of high-level quinolone-resistant *Haemophilus* species that have been isolated from both adults and children.

The genus *Haemophilus* includes 9 bacterial species that cause infections only among humans: *H. influenzae*, *H. aegyptius*, *H. haemolyticus*, *H. parainfluenzae*, *H. parahaemolyticus*, *H. paraphrohaemolyticus*, *H. pittmaniae*, *H. sputorum*, and *H. ducreyi* (1). Among them, *H. influenzae* is a notable causative pathogen of respiratory infections and otitis media in children (2-4). *H. haemolyticus*, which is genetically similar to *H. influenzae* and coexists with *H. influenzae* in the upper respiratory tract (1,5), is considered a commensal

bacterium, and its pathogenicity has not been widely examined. However, some previous studies have reported that *H. haemolyticus* can be misidentified as *H. influenzae* in the clinical setting (6-8).

β -lactams and quinolones are commonly used to treat infections caused by both *H. influenzae* and *H. haemolyticus*. Recently, an increase in *H. influenzae* strains with reduced susceptibility to quinolones has been reported (9-11). Moreover, high-level resistant strains (MIC for levofloxacin ≥ 8 $\mu\text{g}/\text{mL}$) of *H. influenzae* have also emerged (12-15) but have been isolated only from adult case-patients (11,12). Recent nationwide surveillance in Japan indicated that quinolone-resistant *H. influenzae* had not been isolated among pediatric patients (16). Although low-susceptibility strains of *H. haemolyticus* have emerged, a high-level resistance strain had not been isolated from a pediatric patient (17). We isolated the *H. haemolyticus* strain 2019-19, which showed high-level resistance to quinolones, from a pediatric patient in an acute care hospital in Tokyo, Japan, and analyzed the features of the strain and case background of the patient.

Materials and Methods

Patient Characteristics

A 9-year-old girl with severe motor and intellectual disabilities, hypothyroidism, and chronic respiratory disease was hospitalized for hypoxic ischemic encephalopathy in the Tokyo University of Hachioji Medical Centre (Tokyo, Japan). The patient had been under mechanical ventilation related to tracheostomy since she was 7 years of age and had not been administered any quinolones for ≥ 3 years before hospitalization. Because the patient had a

Author affiliations: Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan (E. Tanaka, T. Wajima, H. Nakaminami); Meijo University, Nagoya, Japan (E. Tanaka, T. Wajima); Tokyo Medical University Hachioji Medical Centre, Tokyo (Y. Hirai, Y. Ishida); Aichi Gakuin University, Nagoya, Japan (Y. Kawamura)

DOI: <https://doi.org/10.3201/eid2801.210248>

¹These authors contributed equally to this article.

fever with increased sputum production after 3 days of hospitalization, we obtained a suction sputum culture and administered ampicillin/sulbactam intravenously to her for 1 week. The patient was discharged because her fever resolved after 5 days of hospitalization.

Bacterial Isolation and Culture Conditions

We isolated *H. haemolyticus* (strain identification 2019-19) from the suction sputum and identified it as quinolone-resistant *H. influenzae* by routine laboratory testing using a MicroScan WalkAway system (Siemens, <https://www.siemens.com>). Because quinolone-resistant *H. influenzae* had never been isolated from a pediatric patient, we performed a detailed susceptibility test for 2019-19 by the broth microdilution method. For controls in the biochemical test, we used *H. influenzae* GTC 14202^T (DSM 4690^T) and *H. haemolyticus* GTC 15009^T (NCTC 10659^T) type strains purchased from Gifu University (<https://www.gifu-u.ac.jp>). In addition, we used *H. influenzae* ATCC 49247 and Rd as quality control strains for antimicrobial susceptibility testing. We cultured the isolates overnight on chocolate agar at 37°C in a 5% CO₂ atmosphere and stored them in 10% skim milk at -80°C until use. This study was approved by the research ethics committees at the Tokyo University of Pharmacy and Life Sciences (case no. 16-12).

Antimicrobial Susceptibility Test

We measured MICs by broth microdilution method as described by the Clinical and Laboratory Standards Institute (18). As tested agents, we used ampicillin, amoxicillin, clavulanic acid, cefotaxime, meropenem, clarithromycin, azithromycin, levofloxacin, tosufloxacin, and moxifloxacin. In addition, we used PAβN (Phe-Arg β-naphthylamide dihydrochloride; Sigma-Aldrich; <https://www.sigmaaldrich.com>) and reserpine (Sigma-Aldrich) as efflux pump inhibitors. We set antimicrobial-susceptible breakpoints according to Clinical and Laboratory Standard Institute criteria (18).

Genomic Analysis

We extracted genomic DNA using a Wizard Genomic DNA purification kit (Promega, <https://www.promega.com>) and sequenced it using GridION (Oxford Nanopore Technologies, <https://nanoporetech.com>) and DNB Seq-G400 (MGI Tech, <https://en.mgi-tech.com>) according to manufacturer instructions. We assembled the sequenced data with Unicycler version 0.4.7 (<https://github.com/rrwick/Unicycler>) with

default parameters, assessed the quality of the genome using CheckM, version 1.0.12 (<https://github.com/Ecogenomics/CheckM>), and annotated the assembled genome sequence using DDBJ's DFAST Fast Annotation and Submission Tool; <https://dfast.nig.ac.jp>). The obtained and annotated sequence data were registered in the DDBJ database under DDBJ/EMBL/GenBank accession number AP024093.

Because the genome sequence of the type strain was not available, we used *H. haemolyticus* NCTC 10839, along with *H. influenzae* ATCC 33391^T, to compare the entire genomes with strain 2019-19, using Easyfig version 2.2.2 (19). We calculated the average nucleotide identity (ANi) algorithm using BLAST (<https://blast.ncbi.nlm.nih.gov/Blast.cgi>) with JSpeciesWS (20) and digital DNA-DNA hybridization (dDDH) using the type strain genome server (21). In addition, we estimated the presence of CRISPR sequences and *cas* genes in the genome using the CRISPRfinder program (22).

Phylogenetic Analysis of Typical Genes

We illustrated a phylogenetic dendrogram using typical genes (16S rDNA sequence, *adk*, *pgi*, *recA*, *infB*, *gyrA*, *gyrB*, *parC*, *parE*, and *ftsI*) with Clustal Omega alignment and the neighbor-joining method of Jukes-Cantor using Geneious Prime 2019 (Biomatters, <https://www.geneious.com>). We selected the 16S rDNA sequence, *adk*, *pgi*, *recA*, and *infB* because they were used in a previous classification study (1,23). In addition, we used *gyrA*, *gyrB*, *parC*, *parE*, and *ftsI* as antimicrobial-targeting genes. We used nucleotide sequences of *Escherichia coli* ATCC 11775^T as an outgroup.

Biochemical Test

We used an API NH kit (bioMérieux, <https://www.biomerieux.com>) to assay biochemical characteristics, prepare bacterial cultures, and interpret the results according to manufacturer protocols. We evaluated use of the V factor, X factor, and several nutrients using *Haemophilus* ID Quad with growth factors agar (BD Biosciences, <https://www.bdbiosciences.com>). We cultured the agar plates overnight at various temperatures (4°C, 16°C, 25°C, 37°C, and 42°C).

Mass Spectrometry

We prepared samples by ethanol/formic acid extraction. One loop of bacteria was suspended in 300 μL distilled water and 900 μL of ethanol was added into the suspension. After centrifuging and discarding the supernatant, we mixed 20 μL each of 70% formic acid and acetonitrile. Next, we applied 1 μL of supernatant

on the target plate and mixed it with 1 μ L HCCA matrix (Bruker, <https://www.bruker.com>). We obtained the spectrum using a matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) MS Bruker autoflex maX and analyzed the phylogenetic tree using MALDI Biotyper Compass Explorer version 4.1.60 (Bruker).

Amino Acid Substitutions of GyrA, GyrB, ParC, and ParE

We estimated amino acid substitutions of DNA gyrase and topoisomerase IV from the nucleotide sequences of *gyrA*, *gyrB*, *parC*, and *parE*. We compared the substitutions with *H. haemolyticus* CCUG 12834^T or ATCC 33390^T (DDBJ/EMBL/GenBank accession no. LYCK01000011, LYCK01000013, or JTLY01000001),




Figure. Genomic analysis of *Haemophilus haemolyticus* strain 2019-19 from a 9-year-old girl in Japan. A) Circular map of the whole-genome sequence. The outermost circle shows the number of nucleotides, the second circle shows coding sequences on the plus strand, and the third circle shows coding sequences on the minus strand. The innermost circle represents the G+C skew (%) and second innermost circle, G+C content (%); green zones show the locations of *gyrA* and *parC*, and blue and light blue zones show CRISPR-Cas-associated genes. Map drawn using Artemis DNA Plotter (Wellcome Sanger institute, Hinxton, UK). G+C, guanine + cytosine. B, C) Comparison between the whole genomes of 2019-19 and *H. haemolyticus* NCTC 10839 (B) and *H. influenzae* ATCC 33391^T (C), created using Easyfig version 2.2.2 (19). Red indicates matches in the same direction; blue indicates inverted matches; white areas indicate nonmatches.

Table 1. Comparison of biochemical characteristics of *Haemophilus haemolyticus* strain 2019-19 from a 9-year-old girl in Japan and reference species*

Characteristics	2019-19	GTC 14202 ^T	GTC 15009 ^T
V-factor requirement	+	+	+
X-factor requirement	+	+	+
Indole production	+	+	-
Urease	+	+	+
Lipase	-	-	-
Ornithine decarboxylase	-	-	-
Alkaline phosphatase	+	+	+
Proline arylamidase	-	-	-
β-galactosidase	-	-	-
γ-glutamyltransferase	-	-	-
Acid source			
D-glucose	+	+	+
D-fructose	+	+	+
Maltose	-	-	+
Sucrose	-	-	-
Growth temperature			
4°C	-	-	-
16°C	-	-	-
25°C	-	W	-
37°C	++	++	++
42°C	-	-	-
CO ₂ enhances growth	-	-	-
Hemolysis	-	-	+

*W, weak; -, negative; + positive.

NCTC 10839 (LS483458), M19346 (CP031243), and M28486 (CP031238).

Results

Genomic Analysis

To further characterize the 2019-19 strain in detail, we determined the whole-genome sequence by next generation sequencing (Figure). The genome size was 1,895,310 bp, comprising 1,764 protein-coding sequences, 19 rRNAs, 57 tRNA, and a CRISPR sequence (Figure panel A). Comparing the whole-genome sequence of 2019-19 with that of *H. influenzae* ATCC 33391^T resulted in a dDDH score of 43.4% (95% CI 40.9%–46.0%) and ANIb score of 90.90%, suggesting an extremely low similarity. In contrast, although we observed a large inversion, we found 2019-19

comparatively strongly related to *H. haemolyticus* NCTC 10839 (Figure, panels B, C). The identity scores for 2019-19 with *H. haemolyticus* type strain ATCC 33390^T were 64.1% (95% CI 61.2%–66.9%) for dDDH and 95.38% for ANIb, suggesting great similarity. To further clarify the genetic classification, we performed phylogenetic analyses using typical species house-keeping genes (16S DNA sequence, *adh*, *pgi*, *recA*, *infB*) and antimicrobial targeting genes (*gyrA*, *gyrB*, *parC*, *parE*, and *ftsI*) (Appendix Figure 1, <https://wwwnc.cdc.gov/EID/article/28/1/21-0248-App1.pdf>). In all phylogenetic trees using these genes, 2019-19 was classified in the same cluster as *H. haemolyticus*. In addition, 2019-19 contained a CRISPR sequence but not an IgA protease, which is a putative marker for distinguishing it from *H. influenzae* (data not shown) (8).

Biochemical Tests

Because we identified this strain as *H. influenzae* by routine laboratory testing, we also investigated the biochemical characteristics of 2019-19 (Table 1). In comparison with the type strains of both *H. haemolyticus* and *H. influenzae*, all biochemical results completely matched with *H. influenzae*. In addition, we identified species on the basis of these results using Apiweb (bioMérieux), which indicated that 2019-19 had 99.9% identity with *H. influenzae*. According to the method for *H. influenzae* described elsewhere, 2019-19 was determined to be biotype II (1).

Mass Spectrometry

MALDI-TOF mass spectrometry analysis is one of the most reliable methods for identifying bacterial species (24,25). The bacterial protein profile was assayed to identify the bacterial species of 2019-19 using this method. In comparison with the database using MALDI Biotyper Compass Explorer version 4.1.60, 2019-19 matched with *H. haemolyticus* CCUG 12834^T with a score 2.21 and was identified as *H. haemolyticus*. Furthermore, in a phylogenetic dendrogram drawn with representative type strains of *Haemophilus* spp. (Appendix Figure 2), 2019-19 was located close to the *H. haemolyticus* type strain ATCC 33390^T.

Quinolone Resistance Mechanisms

Antimicrobial susceptibility testing of strain 2019-19 showed high MIC values (16 to ≥64 µg/mL) to levofloxacin, tosufloxacin, and moxifloxacin and susceptibility to antimicrobial agents including penicillins, cepheps, and macrolides, but not to quinolones (Table 2). We investigated amino acid substitutions in quinolone-targeting proteins (GyrA, GyrB, ParC, and ParE) by comparing the sequences of *H. haemolyticus*

Table 2. Antimicrobial susceptibility of *Haemophilus haemolyticus* strain 2019-19 from a 9-year-old girl in Japan

Agent	MIC, µg/mL	Decision†
Ampicillin	0.25	S
Amoxicillin/clavulanic acid	0.125	S
Cefotaxime	≤0.063	S
Meropenem	≤0.063	S
Clarithromycin	4	S
Azithromycin	0.5	S
Levofloxacin	16	NS
Tosufloxacin	≥64	ND
Moxifloxacin	64	NS

*S, susceptible; ND, not determined; NS, nonsusceptible

†Decided by Clinical Laboratory and Standards Institute criteria (18).

CCUG 12834^T or ATCC 33390^T, NCTC10839, M19346, and M28486 (Table 3; Appendix Figure 3). The results revealed that 2019-19 had various amino acid substitutions in GyrA, GyrB, ParC, and ParE, including amino acid substitutions (Ser84Leu, Asp88Tyr in *gyrA* and Ser84Arg in *parC*) relevant to reducing susceptibility to quinolones (13,17). We measured the MICs of quinolones in the presence of the efflux pump inhibitors reserpine and PA β N to determine whether the efflux system affected quinolone resistance. There was no substantial difference in the presence or absence of inhibitors. To investigate the origin of this strain, we compared quinolone target genes among *Haemophilus* spp.; however, we obtained no evidence of recombination (data not shown).

Discussion

We analyzed high-level quinolone-resistant *H. haemolyticus* strain 2019-19 isolated from a pediatric patient in an acute care hospital in Japan. The patient had several coexisting diseases and had been under tracheotomy for 2 years but had not been exposed to quinolone for the previous ≥ 3 years.

Comparative genome analysis, phylogenetic analysis using typical genes, and MALDI-TOF mass spectrometry analysis indicated that 2019-19 classified into the *H. haemolyticus* cluster rather than *H. influenzae*. Absence of IgA protease supported these results (8). In addition, this strain contained CRISPR sequences. Comparing genome sequences in the database, all *H. haemolyticus* contained CRISPR but *H. influenzae* sequences did not, which might support that this strain was *H. haemolyticus*. In contrast, 2019-19 shared biochemical features with *H. influenzae*. The biotype of 2019-19, biotype II, is the predominant type among *H. influenzae* and comparatively rare among *H. haemolyticus* (17,26,27), making it a notable feature of *H. haemolyticus* 2019-19. Previous studies reported that clinical isolates identified as *H. influenzae* occasionally included *H. haemolyticus* without hemolysis (6–8). The biochemical features of 2019-19 likely contributed to this misidentification. Genomic analysis showed 2019-19 contained a large inversion compared with other *H. haemolyticus* strains; however, the relationship of this inversion with biochemical features was not determined. Bacterial species defined by whole-genome sequence similarity have been reported to be $\approx 95\%$ – 96% ANIb (28) or 70% DDH (29). Although we tentatively identified 2019-19 as *H. haemolyticus*, these definitions and our ANIb and dDDH values suggest that this strain is a novel subspecies or species. The classification data for *Haemophilus* spp. are inadequate compared with those of other

Table 3. Amino acid substitutions in quinolone target protein of *Haemophilus haemolyticus* strain 2019-19 from a 9-year-old girl in Japan*

GyrA	GyrB	ParC	ParE
S84L	A567T	S84R	P439S
D88Y	N631S	S138T	L502F
H212Y	A725V	V214I	D596N
T251S		V270I	A599S
D740E		D442N	
S784N		M591I	
		A641E	

*Compared with *H. haemolyticus* CCUG 12834^T or ATCC 33390^T, NCTC10839, M19346, and M28486

pathogens and species may need to be reclassified after additional genome and biochemical data are accumulated. Our findings can help improve the accuracy of classification and 2019-19 may be designated a novel subspecies or species in the future (6,30).

H. haemolyticus 2019-19 showed high-level quinolone-resistance and multiple amino acid substitutions in quinolone-targeting proteins, which are known to contribute to high-level quinolone resistance (12–14,17,31). In addition, quinolone-resistant *H. parainfluenzae* has been reported (32,33) in Taiwan and Europe and these isolates showed various amino acid substitutions in quinolone target genes, like those observed in 2019-19. Frequent use of quinolone can contribute to the emergence of resistant strains, and although this patient had not been exposed to any quinolones during the previous ≥ 3 years, she had frequently stayed in medical facilities and other antimicrobial agents had been used to treat her multiple coexisting diseases. Moreover, quinolones have been used for pediatric patients in Japan and the frequency of low-susceptibility strains of *H. influenzae* has been increasing (9,10,34). There may be selective pressure not only in hospitals but also in communities. In fact, 2019-19 contained a large inversion in the genome and partially differed from *H. haemolyticus*, suggesting substantial genetic recombination and rearrangement for this strain.

Among the study's limitations, we analyzed only 1 high-level quinolone-resistant *H. haemolyticus* and its prevalence in both community and clinical settings remains unclear. In addition, there was no evidence about whether 2019-19 is a causative pathogen or commensal strain. However, the presence of high-level antimicrobial-resistant *Haemophilus* spp. in children should be noted, because even commensal bacteria can cause lethal infections in immunocompromised hosts.

The reasons why high-level quinolone-resistant *Haemophilus* spp. had not been isolated from children are unclear. A previous report suggested that quinolones have not been used to treat pediatric infections

(11). In addition, because *H. influenzae* is a commensal nasopharyngeal bacteria for most children (35), quinolone-resistant strains may be outcompeted by other commensal bacteria. The adaptability of quinolone-resistant strains should be further analyzed.

In conclusion, our findings reveal the existence of high-level quinolone-resistant *Haemophilus* spp. strains in children. Horizontal gene transfer between *H. influenzae* and *H. haemolyticus* has been observed (36,37), and high-level quinolone-resistant *H. influenzae* may also emerge. Therefore, the presence of high-level resistance strains should be considered when quinolones are used to treat children.

This work was partially supported by Sasakawa Scientific Research (grant no. 2020-4001) from the Japan Science Society (E.T.) and Nagai Memorial Research Scholarship (no. N-202604) from the Pharmaceutical Society of Japan (E.T.).

About the Author

Ms. Tanaka is a PhD student at Tokyo University of Pharmacy and Life Sciences. Her research interests are epidemiological trends and the antimicrobial resistance mechanism of *Haemophilus* species.

References


- Nørskov-Lauritsen N. Classification, identification, and clinical significance of *Haemophilus* and *Aggregatibacter* species with host specificity for humans. *Clin Microbiol Rev*. 2014;27:214–40. <https://doi.org/10.1128/CMR.00103-13>
- Adachi Y, Ando M, Morozumi M, Ubukata K, Iwata S. Genotypic characterization of *Haemophilus influenzae* isolates from paediatric patients in Japan. *J Med Microbiol*. 2018;67:695–701. <https://doi.org/10.1099/jmm.0.000721>
- Kilian M. Genus III. *Haemophilus*. Winslow, Broadhurst, Buchanan, Rogers and Smith 1917. In: Brenner DJ, Krieg NR, Staley JT, Garrity GM, editors. *Bergey's manual of systematic bacteriology*, 2nd ed., vol. 2. The proteobacteriaceae. Part B. The gammaproteobacteria. New York: Springer; 2005. p. 883–904.
- Murphy TF, Brauer AL, Sethi S, Kilian M, Cai X, Lesse AJ. *Haemophilus haemolyticus*: a human respiratory tract commensal to be distinguished from *Haemophilus influenzae*. *J Infect Dis*. 2007;195:81–9. <https://doi.org/10.1086/509824>
- Kirkham LA, Wiertsema SP, Mowe EN, Bowman JM, Riley TV, Richmond PC. Nasopharyngeal carriage of *Haemophilus haemolyticus* in otitis-prone and healthy children. *J Clin Microbiol*. 2010;48:2557–9. <https://doi.org/10.1128/JCM.00069-10>
- McCrea KW, Xie J, LaCross N, Patel M, Mukundan D, Murphy TF, et al. Relationships of nontypeable *Haemophilus influenzae* strains to hemolytic and nonhemolytic *Haemophilus haemolyticus* strains. *J Clin Microbiol*. 2008;46:406–16. <https://doi.org/10.1128/JCM.01832-07>
- Mukundan D, Ecevit Z, Patel M, Marrs CF, Gilsdorf JR. Pharyngeal colonization dynamics of *Haemophilus influenzae* and *Haemophilus haemolyticus* in healthy adult carriers. *J Clin Microbiol*. 2007;45:3207–17. <https://doi.org/10.1128/JCM.00492-07>
- Hotomi M, Kono M, Togawa A, Arai J, Takei S, Ikeda Y, et al. *Haemophilus influenzae* and *Haemophilus haemolyticus* in tonsillar cultures of adults with acute pharyngotonsillitis. *Auris Nasus Larynx*. 2010;37:594–600. <https://doi.org/10.1016/j.anl.2010.02.005>
- Seyama S, Wajima T, Yanagisawa Y, Nakaminami H, Ushio M, Fujii T, et al. Rise in *Haemophilus influenzae* with reduced quinolone susceptibility and development of a simple screening method. *Pediatr Infect Dis J*. 2017;36:263–6. <https://doi.org/10.1097/INF.0000000000001415>
- Tanaka E, Hara N, Wajima T, Ochiai S, Seyama S, Shirai A, et al. Emergence of *Haemophilus influenzae* with low susceptibility to quinolones and persistence in tosofloxacin treatment. *J Glob Antimicrob Resist*. 2019;18:104–8. <https://doi.org/10.1016/j.jgar.2019.01.017>
- Yokota S, Ohkoshi Y, Sato K, Fujii N. Emergence of fluoroquinolone-resistant *Haemophilus influenzae* strains among elderly patients but not among children. *J Clin Microbiol*. 2008;46:361–5. <https://doi.org/10.1128/JCM.01561-07>
- Cherkaoui A, Gaia N, Baud D, Leo S, Fischer A, Ruppe E, et al. Molecular characterization of fluoroquinolones, macrolides, and imipenem resistance in *Haemophilus influenzae*: analysis of the mutations in QRDRs and assessment of the extent of the AcrAB-TolC-mediated resistance. *Eur J Clin Microbiol Infect Dis*. 2018;37:2201–10. <https://doi.org/10.1007/s10096-018-3362-z>
- Puig C, Tirado-Vélez JM, Calatayud L, Tubau F, Garmendia J, Ardanuy C, et al. Molecular characterization of fluoroquinolone resistance in nontypeable *Haemophilus influenzae* clinical isolates. *Antimicrob Agents Chemother*. 2015;59:461–6. <https://doi.org/10.1128/AAC.04005-14>
- Tateda K, Ohno A, Ishii Y, Murakami H, Yamaguchi K; Levofloxacin surveillance group. Investigation of the susceptibility trends in Japan to fluoroquinolones and other antimicrobial agents in a nationwide collection of clinical isolates: A longitudinal analysis from 1994 to 2016. *J Infect Chemother*. 2019;25:594–604. <https://doi.org/10.1016/j.jiac.2019.03.008>
- Yamada S, Seyama S, Wajima T, Yuzawa Y, Saito M, Tanaka E, et al. β -Lactamase-non-producing ampicillin-resistant *Haemophilus influenzae* is acquiring multidrug resistance. *J Infect Public Health*. 2020;13:497–501. <https://doi.org/10.1016/j.jiph.2019.11.003>
- Ishiwada N, Fujimaki K, Matsumoto T, Kiyota H, Tateda K, Sato J, et al. Nationwide surveillance of bacterial pathogens isolated from children conducted by the surveillance committee of Japanese Society of Chemotherapy, the Japanese Association for Infectious Diseases, and the Japanese Society for Clinical Microbiology in 2017: General overview of pathogenic antimicrobial susceptibility. *J Infect Chemother*. 2021;27:139–50. <https://doi.org/10.1016/j.jiac.2020.11.020>
- Marti S, Puig C, de la Campa AG, Tirado-Velez JM, Tubau F, Domenech A, et al. Identification of *Haemophilus haemolyticus* in clinical samples and characterization of their mechanisms of antimicrobial resistance. *J Antimicrob Chemother*. 2016;71:80–4. <https://doi.org/10.1093/jac/dkv307>
- Clinical Laboratory and Standards Institute. Performance standards for antimicrobial susceptibility testing (M100). 29th ed. Wayne (PA): The Institute; 2019.
- Sullivan MJ, Petty NK, Beatson SA. Easyfig: a genome comparison visualizer. *Bioinformatics*. 2011;27:1009–10. <https://doi.org/10.1093/bioinformatics/btr039>


20. Richter M, Rosselló-Móra R, Oliver Glöckner F, Peplies J. JSpeciesWS: a web server for prokaryotic species circumscription based on pairwise genome comparison. *Bioinformatics*. 2016;32:929–31. <https://doi.org/10.1093/bioinformatics/btv681>
21. Meier-Kolthoff JP, Göker M. TYGS is an automated high-throughput platform for state-of-the-art genome-based taxonomy. *Nat Commun*. 2019;10:2182. <https://doi.org/10.1038/s41467-019-10210-3>
22. Grissa I, Vergnaud G, Pourcel C. CRISPRFinder: a web tool to identify clustered regularly interspaced short palindromic repeats. *Nucleic Acids Res*. 2007;35(Web Server issue):W52–7.
23. Christensen H, Kuhnert P, Olsen JE, Bisgaard M. Comparative phylogenies of the housekeeping genes *atpD*, *infB* and *rpoB* and the 16S rRNA gene within the *Pasteurellaceae*. *Int J Syst Evol Microbiol*. 2004;54:1601–9. <https://doi.org/10.1099/ijs.0.03018-0>
24. Bruin JP, Kostrzewa M, van der Ende A, Badoux P, Jansen R, Boers SA, et al. Identification of *Haemophilus influenzae* and *Haemophilus haemolyticus* by matrix-assisted laser desorption ionization-time of flight mass spectrometry. *Eur J Clin Microbiol Infect Dis*. 2014;33:279–84. <https://doi.org/10.1007/s10096-013-1958-x>
25. Saffert RT, Cunningham SA, Ihde SM, Monson Jobe KE, Mandrekar J, Patel R. Comparison of Bruker Biotyper matrix-assisted laser desorption ionization-time of flight mass spectrometer to BD Phoenix automated microbiology system for identification of gram-negative bacilli. *J Clin Microbiol*. 2011;49:887–92. <https://doi.org/10.1128/JCM.01890-10>
26. Collins S, Vickers A, Ladhani SN, Flynn S, Platt S, Ramsay ME, et al. Clinical and molecular epidemiology of childhood invasive nontypeable *Haemophilus influenzae* disease in England and Wales. *Pediatr Infect Dis J*. 2016;35:e76–84. <https://doi.org/10.1097/INF.0000000000000996>
27. Lulitanond A, Chanawong A, Pienthaweechai K, Sribenjalux P, Tavichakorntrakool R, Wilailuckana C, et al. Prevalence of β -lactamase-negative ampicillin-resistant *haemophilus influenzae* isolated from patients of a teaching hospital in Thailand. *Jpn J Infect Dis*. 2012;65:122–5.
28. Richter M, Rosselló-Móra R. Shifting the genomic gold standard for the prokaryotic species definition. *Proc Natl Acad Sci U S A*. 2009;106:19126–31. <https://doi.org/10.1073/pnas.0906412106>
29. Meier-Kolthoff JP, Auch AF, Klenk HP, Göker M. Genome sequence-based species delimitation with confidence intervals and improved distance functions. *BMC Bioinformatics*. 2013;14:60. <https://doi.org/10.1186/1471-2105-14-60>
30. Harris TM, Price EP, Sarovich DS, Nørskov-Lauritsen N, Beissbarth J, Chang AB, et al. Comparative genomic analysis identifies X-factor (haemin)-independent *Haemophilus haemolyticus*: a formal re-classification of ‘*Haemophilus intermedius*’. *Microb Genom*. 2020;6:e000303. <https://doi.org/10.1099/mgen.0.000303>
31. Georgiou M, Muñoz R, Román F, Cantón R, Gómez-Lus R, Campos J, et al. Ciprofloxacin-resistant *Haemophilus influenzae* strains possess mutations in analogous positions of GyrA and ParC. *Antimicrob Agents Chemother*. 1996;40:1741–4. <https://doi.org/10.1128/AAC.40.7.1741>
32. Chang CM, Tang HJ, Wang LR, Shih HI, Huang CC, Lee NY, et al. Increasing resistance to fluoroquinolones among *Haemophilus* species in Southern Taiwan. *J Microbiol Immunol Infect*. 2017;50:258–60. <https://doi.org/10.1016/j.jmii.2016.04.002>
33. Rodríguez-Martínez JM, López-Hernández I, Pascual A. Molecular characterization of high-level fluoroquinolone resistance in a clinical isolate of *Haemophilus parainfluenzae*. *J Antimicrob Chemother*. 2011;66:673–5. <https://doi.org/10.1093/jac/dkq473>
34. Mikasa K, Aoki N, Aoki Y, Abe S, Iwata S, Ouchi K, et al. JAID/JSC guidelines for the treatment of respiratory infectious diseases: the Japanese Association for Infectious Diseases/Japanese Society of Chemotherapy – the JAID/JSC guide to clinical management of infectious disease/Guideline-preparing Committee Respiratory Infectious Disease WG. *J Infect Chemother*. 2016;22(Suppl):S1–65. <https://doi.org/10.1016/j.jiac.2015.12.019>
35. Wouters I, Desmet S, Van Heirstraeten L, Herzog SA, Beutels P, Verhaegen J, et al. NPcarriage Study Group. How nasopharyngeal pneumococcal carriage evolved during and after a PCV13-to-PCV10 vaccination programme switch in Belgium, 2016 to 2018. *Euro Surveill*. 2020;25:1900303. <https://doi.org/10.2807/1560-7917.ES.2020.25.5.1900303>
36. Takahata S, Ida T, Senju N, Sanbongi Y, Miyata A, Maebashi K, et al. Horizontal gene transfer of *ftsI*, encoding penicillin-binding protein 3, in *Haemophilus influenzae*. *Antimicrob Agents Chemother*. 2007;51:1589–95. <https://doi.org/10.1128/AAC.01545-06>
37. Witherden EA, Bajanca-Lavado MP, Tristram SG, Nunes A. Role of inter-species recombination of the *ftsI* gene in the dissemination of altered penicillin-binding-protein-3-mediated resistance in *Haemophilus influenzae* and *Haemophilus haemolyticus*. *J Antimicrob Chemother*. 2014;69:1501–9. <https://doi.org/10.1093/jac/dku022>


Address for correspondence: Takeaki Wajima, Ph.D, Meijo University, 150 Yagotoyama, Tenpaku, Nagoya 468-8503, Japan; email: twajima@meijo-u.ac.jp


Appendix


High-Level Quinolone-Resistant *Haemophilus haemolyticus* in a Pediatric Patient with No History of Quinolone Exposure



























Appendix Figure 1. Neighbor-joining dendrograms based on nucleotide sequences. The dendrograms were drawn based on the nucleotide sequence of typical genes. They were drawn using the Clustal Omega program and neighbor-joining method using Geneious prime 2019 (Biomatters, <https://www.geneious.com>). *Escherichia coli* ATCC 11775^T was considered an outgroup. Panels A) 16S rDNA nucleotide sequences, B) *adk*, C) *pgi*, D) *recA*, E) *infB*, F) *gyrA*, G) *gyrB*, H) *parC*, I) *parE*, and J) *ftsI*. *H.*, *Haemophilus*



Appendix Figure 2. Main spectra library dendrogram of MALDI-TOF mass spectral profiles. The dendrogram was generated using MBT Compass Explorer 4.1.60 software (Bruker, <https://www.bruker.com>) on the basis of the MALDI-TOF mass spectral profiles of 10 *Haemophilus* spp. *H.*, *Haemophilus*

A	<i>H. haemolyticus</i> 2019-19	1	MTDSIQSITPPVNIIEEELKSYLDYAMSVIVGRALEDVDRDLKPKVHRVRLVFLSMDREGNTANKKYVKSARVSVGVIGKYPHGD AVY TIVRMAQPFSLR	100
	<i>H. haemolyticus</i> CCUG 12834 ^T	1S.....D.....	100
	<i>H. haemolyticus</i> NCTC 10839	1S.....D.....	100
	<i>H. haemolyticus</i> M19346	1S.....D.....	100
	<i>H. haemolyticus</i> M28486	1S.....D.....	100
	<i>H. haemolyticus</i> 2019-19	101	YMLVDGQGNFGSIDGDAPAAAMRYTEVRMOKITQALLTDLKRTVNFSPMYDGEIMLDPVLTRIPALLANGSSGIAVGMATNIFPHNLNEVLNGCLAYID	200
	<i>H. haemolyticus</i> CCUG 12834 ^T	101	200
	<i>H. haemolyticus</i> NCTC 10839	101	200
	<i>H. haemolyticus</i> M19346	101	200
	<i>H. haemolyticus</i> M28486	101	200
	<i>H. haemolyticus</i> 2019-19	201	NNEITIDELMQ IPGDFPTAALINGRKGIEEAYRTPRGRKYVVRARATVE NEKGRGQIIVSELPIYQUNKAKLVEKIAELIPEKIKIGISNITDLSNKEG	300
	<i>H. haemolyticus</i> CCUG 12834 ^T	201H.....T.....	300
	<i>H. haemolyticus</i> NCTC 10839	201H.....T.....	300
	<i>H. haemolyticus</i> M19346	201H.....T.....	300
	<i>H. haemolyticus</i> M28486	201H.....T.....	300
	<i>H. haemolyticus</i> 2019-19	301	IRIEIDIKRDAVGEVVLNHLVSLTMCQVTFGINMVALDHGQPLFLNKEIIE FVLHRRVVTTRRSIFELFKARERTHILEGLAVARNIDEMIAITRNS	400
	<i>H. haemolyticus</i> CCUG 12834 ^T	301	400
	<i>H. haemolyticus</i> NCTC 10839	301A.....	400
	<i>H. haemolyticus</i> M19346	301A.....	400
	<i>H. haemolyticus</i> M28486	301A.....	400
	<i>H. haemolyticus</i> 2019-19	401	KNREBAATLSSRSMTLHSDIILMLDVSARPPDLEENLGIQGGQVLYSPAQUNALIELRLHRLTGLAFEEVVEVEELLVKADLHLHLSAERLMEVIR	500
	<i>H. haemolyticus</i> CCUG 12834 ^T	401	500
	<i>H. haemolyticus</i> NCTC 10839	401	500
	<i>H. haemolyticus</i> M19346	401	500
	<i>H. haemolyticus</i> M28486	401	500
	<i>H. haemolyticus</i> 2019-19	501	EELVEVKAQFGDRLTEITAASGDIDLEDLIAQEDVVVTLSEHGVKYPQLTDYEAQRGGKGSATFMKEEDFIEKLLVANHTDITLFCSSRGLVWLK	600
	<i>H. haemolyticus</i> CCUG 12834 ^T	501	600
	<i>H. haemolyticus</i> NCTC 10839	501	600
	<i>H. haemolyticus</i> M19346	501	600
	<i>H. haemolyticus</i> M28486	501	600
	<i>H. haemolyticus</i> 2019-19	601	VYQLPQASRGARGPVNLPLQENRITAIIEVSAVBEKDFVUMATAGGIVKIKIALTEFSPRPRNGIALLNLRDEDELIGVDITDGSNEMIMFSSQGRV	700
	<i>H. haemolyticus</i> CCUG 12834 ^T	601	700
	<i>H. haemolyticus</i> NCTC 10839	601	700
	<i>H. haemolyticus</i> M19346	601	700
	<i>H. haemolyticus</i> M28486	601	700
	<i>H. haemolyticus</i> 2019-19	701	VRPABNAVAMGRLATVGRGIKALITNDISDESAVEIE ISDDNABASLDLNDIKVUSLVVPEKGAITATONGYKRTQL EYPTKSRNTRGVISIR	800
	<i>H. haemolyticus</i> CCUG 12834 ^T	701D.....S.....	800
	<i>H. haemolyticus</i> NCTC 10839	701D.....S.....	800
	<i>H. haemolyticus</i> M19346	701D.....S.....	800
	<i>H. haemolyticus</i> M28486	701D.....S.....	800
	<i>H. haemolyticus</i> 2019-19	801	VSRNGKVVAATQVEETDQIMLITDAGTLVRRVRSVSIUGRNTGGVLIIRADDEHVUSLERVCDADSEDSLEESGSEE	880
	<i>H. haemolyticus</i> CCUG 12834 ^T	801	880
	<i>H. haemolyticus</i> NCTC 10839	801	880
	<i>H. haemolyticus</i> M19346	801	880
	<i>H. haemolyticus</i> M28486	801	880

B	<i>H. haemolyticus</i> 2019-19	1	MSETTNDNYGASSIKVLKGLDAVRRRPGRYIGDPTDGGTGLHMMVFEVVDNMAIDELAGHCSDIIVTTHDDNSVSVQDDGRGIPVDIMPEBEGVAAAEVIMT	100
	<i>H. haemolyticus</i> CCUG 12834 ^T	1	100
	<i>H. haemolyticus</i> NCTC 10839	1	100
	<i>H. haemolyticus</i> M19346	1	100
	<i>H. haemolyticus</i> M28486	1	100
	<i>H. haemolyticus</i> 2019-19	101	VHAGGKFPDNYKVSQGLHSGVSVVNALSDKLGTLTRQGHVHQPYHLGEPQAPLTVIGDTEATGTTVRFWFS SDIFAITTFDYKLLAKRLBELSPL	200
	<i>H. haemolyticus</i> CCUG 12834 ^T	101	200
	<i>H. haemolyticus</i> NCTC 10839	101	200
	<i>H. haemolyticus</i> M19346	101	200
	<i>H. haemolyticus</i> M28486	101	200
	<i>H. haemolyticus</i> 2019-19	201	NSGVSRILDKRDGSDHFFYEGGIQAFVEYLNKMKMIPHPFPFYTAERDKGIGVEVALQNDGVNENVYCFPTNNIPQRDGGTHLAGFRGALTRSLNSYM	300
	<i>H. haemolyticus</i> CCUG 12834 ^T	201	300
	<i>H. haemolyticus</i> NCTC 10839	201	300
	<i>H. haemolyticus</i> M19346	201	300
	<i>H. haemolyticus</i> M28486	201	300
	<i>H. haemolyticus</i> 2019-19	301	ENSGMLKKEKVAATSGDAREGLVAILSVKVPDPKFFSQKDKLVSSEVKSVAESAMNEKMQEYLLNFPADAKIIVNQIIMAAARAAARKAREMTRRKA	400
	<i>H. haemolyticus</i> CCUG 12834 ^T	301	400
	<i>H. haemolyticus</i> NCTC 10839	301	400
	<i>H. haemolyticus</i> M19346	301	400
	<i>H. haemolyticus</i> M28486	301	400
	<i>H. haemolyticus</i> 2019-19	401	LDIAGLPGKLADCOEKDFALSELYLVEGDSAGSARKVGRDRKTCALLKGLKILNVEKARFDMLS SQEVTGLITLALGCGIGRDEYNPKLRYHHILIMT	500
	<i>H. haemolyticus</i> CCUG 12834 ^T	401	500
	<i>H. haemolyticus</i> NCTC 10839	401	500
	<i>H. haemolyticus</i> M19346	401	500
	<i>H. haemolyticus</i> M28486	401	500
	<i>H. haemolyticus</i> 2019-19	501	DADVDSGSHIRTLLETPFVQMPLEIERSGVYVIAQPELYVYKRGKGRVIRIDADEMQEYELTALDG ELHISANAPANHALVFEKLVAEYHSVQKLIQRL	600
	<i>H. haemolyticus</i> CCUG 12834 ^T	501A.....	600
	<i>H. haemolyticus</i> NCTC 10839	501A.....	600
	<i>H. haemolyticus</i> M19346	501A.....	600
	<i>H. haemolyticus</i> M28486	501A.....	600
	<i>H. haemolyticus</i> 2019-19	601	SRHYFAPVLQGLIYQSPISVEMKDESARE WSKSFVQLTAKETAHQVSVRTQFNAERQVYEA VITVYRKHGIDTDYFLNDFVHGHYAKIVSLKQL	700
	<i>H. haemolyticus</i> CCUG 12834 ^T	601N.....	700
	<i>H. haemolyticus</i> NCTC 10839	601N.....	700
	<i>H. haemolyticus</i> M19346	601N.....	700
	<i>H. haemolyticus</i> M28486	601N.....	700
	<i>H. haemolyticus</i> 2019-19	701	NGLLEBAGYVTRGEKVQ VRSFEQ VEWLVKE SRKLEVQRVYKGLGEMNADQLWETTMDPNSRRMLKVSIKDAVAADQLFTLMDGEVEPRREFIELNAL	800
	<i>H. haemolyticus</i> CCUG 12834 ^T	701P.....A.....	800
	<i>H. haemolyticus</i> NCTC 10839	701P.....A.....	800
	<i>H. haemolyticus</i> M19346	701P.....A.....	800
	<i>H. haemolyticus</i> M28486	701P.....A.....	800
	<i>H. haemolyticus</i> 2019-19	801	RANLDV	806
	<i>H. haemolyticus</i> CCUG 12834 ^T	801	806
	<i>H. haemolyticus</i> NCTC 10839	801	806
	<i>H. haemolyticus</i> M19346	801	806
	<i>H. haemolyticus</i> M28486	801	806

C

<i>H. haemolyticus</i> 2019-19	1	MTNINYGIEQMPLEPTFERAYLVNYSVMVMDRALPTDGLKPVORRIVVAMSBLGNATARKYKKSARTVGSVDLGFHPHGD ACYEAUMVMAQPFYSR	100
<i>H. haemolyticus</i> ATCC 33390 ^f	1S.....	100
<i>H. haemolyticus</i> NCTC 10839	1S.....	100
<i>H. haemolyticus</i> M19346	1S.....	100
<i>H. haemolyticus</i> M28486	1S.....	100
<i>H. haemolyticus</i> 2019-19	101	YPLVDGQGNWAPDDPKSFAAMRYTESRLSKISEILL ELQGQTVDYQPNFDGTLAEPQYLPAFLPHILLNGTGTGIAUVMATDIPPHNINEIDAAMVLL	200
<i>H. haemolyticus</i> ATCC 33390 ^f	101S.....	200
<i>H. haemolyticus</i> NCTC 10839	101S.....	200
<i>H. haemolyticus</i> M19346	101S.....	200
<i>H. haemolyticus</i> M28486	101S.....	200
<i>H. haemolyticus</i> 2019-19	201	DNFKA LDDVLEI QGFDPFTEAEIISPKSEIRKIYBOSRGSINRAATWKKEDGSIILSALPHQSSPSK IAQIABQMTAKKLPNLEDIADADHENFIR	300
<i>H. haemolyticus</i> ATCC 33390 ^f	201G.....V.....	300
<i>H. haemolyticus</i> NCTC 10839	201G.....V.....	300
<i>H. haemolyticus</i> M19346	201G.....V.....	300
<i>H. haemolyticus</i> M28486	201G.....V.....	300
<i>H. haemolyticus</i> 2019-19	301	IVLVPRSNRVDTDALMAHLFATDLEKSYRVMNMMI GLDHPAVKGLLEILNEMIL FRRTVTVRLQVRLDRVLSRLHLEGLMIAPLMIDEVETIRHE	400
<i>H. haemolyticus</i> ATCC 33390 ^f	301T.....	400
<i>H. haemolyticus</i> NCTC 10839	301T.....	400
<i>H. haemolyticus</i> M19346	301T.....	400
<i>H. haemolyticus</i> M28486	301T.....	400
<i>H. haemolyticus</i> 2019-19	401	DDFKAEIMARFNLSDEQADAILNLRHLAKLEENQKABQ ELEKERLNLEALIGSERRLNTLIKKEIQEDAKKYASPPMSQOLVEREAPMISESDMTF	500
<i>H. haemolyticus</i> ATCC 33390 ^f	401D.....	500
<i>H. haemolyticus</i> NCTC 10839	401D.....	500
<i>H. haemolyticus</i> M19346	401D.....	500
<i>H. haemolyticus</i> M28486	401D.....	500
<i>H. haemolyticus</i> 2019-19	501	ABPVTVLSENGWURCAKGHIDIPKELSYKAGDNYRAHACGSKSNQAVVFD STGRSYALDELSPSARSQSEPLTQKLNLEAGATIEYVV ASBEOQLLM	600
<i>H. haemolyticus</i> ATCC 33390 ^f	501M.....	600
<i>H. haemolyticus</i> NCTC 10839	501M.....	600
<i>H. haemolyticus</i> M19346	501M.....	600
<i>H. haemolyticus</i> M28486	501M.....	600
<i>H. haemolyticus</i> 2019-19	601	ASDAGYGFICKFEDLIARNKAGKALISLEFNKAVHMPKTL NATALVVMAMTSAGRMIFP KDLEALSQKGGNKI VTI PAANAKERSSELLV LLLISDQA	700
<i>H. haemolyticus</i> ATCC 33390 ^f	601A.....A.....	700
<i>H. haemolyticus</i> NCTC 10839	601A.....A.....R.....	700
<i>H. haemolyticus</i> M19346	601A.....A.....R.....	700
<i>H. haemolyticus</i> M28486	601A.....A.....R.....	700
<i>H. haemolyticus</i> 2019-19	701	SLEPHSGRRKIVLKPEDLQKRAERGRKGGSTLPRGLHTN EIVVIEPQHNT	751
<i>H. haemolyticus</i> ATCC 33390 ^f	701	751
<i>H. haemolyticus</i> NCTC 10839	701V.....	751
<i>H. haemolyticus</i> M19346	701V.....	750
<i>H. haemolyticus</i> M28486	701V.....	751

D

<i>H. haemolyticus</i> 2019-19	1	MTNINYSQIEITVLKDLPEVQIRFGMYTDTTRNHLAQEVIDNSVDEALAGFATKIEVILHFDQSIKVTNDRGMPVDIHPTEGVSQVEVILT KLHAGGKF	100
<i>H. haemolyticus</i> ATCC 33390 ^f	1	100
<i>H. haemolyticus</i> NCTC 10839	1	100
<i>H. haemolyticus</i> M28486	1	100
<i>H. haemolyticus</i> M19346	1	100
<i>H. haemolyticus</i> 2019-19	101	SNKNYEFAGGLHGVGI SVVNALSERVDIQVRRNGEVYKIAFENGRNVBELEVI GTGSRRTTGTTVHF KENKPYFDSAKFVSRLRHLRAKAVLCSGLEI	200
<i>H. haemolyticus</i> ATCC 33390 ^f	101	200
<i>H. haemolyticus</i> NCTC 10839	101	200
<i>H. haemolyticus</i> M28486	101	200
<i>H. haemolyticus</i> M19346	101	200
<i>H. haemolyticus</i> 2019-19	201	KFIDKVNNTQDIWLYEDGLSDVYLIEAVNGFETLPEKFFVGEFGKTNBAVSWALLWLPPEGSELIGESYVNLIPITIQGGTHVNGLRQGLLDAREFCFRNL	300
<i>H. haemolyticus</i> ATCC 33390 ^f	201	300
<i>H. haemolyticus</i> NCTC 10839	201	300
<i>H. haemolyticus</i> M28486	201	300
<i>H. haemolyticus</i> M19346	201	300
<i>H. haemolyticus</i> 2019-19	301	LERGVKLTADDIWDRCYIILSKMQDAQFAGQTKERLSSRQSAVEVSGVLKDAFSLMNLGNVQDAKRLAEIAISSAQRRLRAAKVVRKILVSGPALPGK	400
<i>H. haemolyticus</i> ATCC 33390 ^f	301	400
<i>H. haemolyticus</i> NCTC 10839	301	400
<i>H. haemolyticus</i> M28486	301	400
<i>H. haemolyticus</i> M19346	301	400
<i>H. haemolyticus</i> 2019-19	401	LADCGSQDLKTELEFLVEGDSAGGSARQARDREYQAIL LRGKIINTWEVSPDQVLSGSTEIHDAVALGIDPDSNDLSQLRYKVCILADADSDGLHIAT	500
<i>H. haemolyticus</i> ATCC 33390 ^f	401P.....	500
<i>H. haemolyticus</i> NCTC 10839	401P.....	500
<i>H. haemolyticus</i> M28486	401P.....	500
<i>H. haemolyticus</i> M19346	401P.....	500
<i>H. haemolyticus</i> 2019-19	501	I CALFLRHFPLKLVQDGHVIVAMPPLRYRIDLNKEVYFALDESEKBAILDRLKNKKGKENVQREKGLGEMNPSQLRETTMDNTRRLVQLTYDLEE QG D	600
<i>H. haemolyticus</i> ATCC 33390 ^f	501L.....D.....A.....	600
<i>H. haemolyticus</i> NCTC 10839	501L.....D.....A.....	600
<i>H. haemolyticus</i> M28486	501L.....D.....A.....	600
<i>H. haemolyticus</i> M19346	501L.....D.....A.....	600
<i>H. haemolyticus</i> 2019-19	601	TLELMDMLLAKKRSSEDRKNWLQAKGDQVDSLVS	632
<i>H. haemolyticus</i> ATCC 33390 ^f	601	632
<i>H. haemolyticus</i> NCTC 10839	601	632
<i>H. haemolyticus</i> M28486	601	632
<i>H. haemolyticus</i> M19346	601	632

Appendix Figure 3. Amino acid alignments of quinolone target proteins. These alignments were created using Genetyx version 10 (<https://www.genetyx.co.jp>). The amino acid substitutions are shown as single character codes. These data are the basis for Table 3. Panels A) *gyrA*, B) *gyrB*, C) *parC*, and D) *parE*. *H., Haemophilus*